172 related articles for article (PubMed ID: 22829238)
1. Drug-mediated inhibition of Fli-1 for the treatment of leukemia.
Li YJ; Zhao X; Vecchiarelli-Federico LM; Li Y; Datti A; Cheng Y; Ben-David Y
Blood Cancer J; 2012 Jan; 2(1):e54. PubMed ID: 22829238
[TBL] [Abstract][Full Text] [Related]
2. Continuous Fli-1 expression plays an essential role in the proliferation and survival of F-MuLV-induced erythroleukemia and human erythroleukemia.
Cui JW; Vecchiarelli-Federico LM; Li YJ; Wang GJ; Ben-David Y
Leukemia; 2009 Jul; 23(7):1311-9. PubMed ID: 19282832
[TBL] [Abstract][Full Text] [Related]
3. Microsatellites as EWS/FLI response elements in Ewing's sarcoma.
Gangwal K; Sankar S; Hollenhorst PC; Kinsey M; Haroldsen SC; Shah AA; Boucher KM; Watkins WS; Jorde LB; Graves BJ; Lessnick SL
Proc Natl Acad Sci U S A; 2008 Jul; 105(29):10149-54. PubMed ID: 18626011
[TBL] [Abstract][Full Text] [Related]
4. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.
Kinsey M; Smith R; Lessnick SL
Mol Cancer Res; 2006 Nov; 4(11):851-9. PubMed ID: 17114343
[TBL] [Abstract][Full Text] [Related]
5. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells.
Tirado OM; Mateo-Lozano S; Villar J; Dettin LE; Llort A; Gallego S; Ban J; Kovar H; Notario V
Cancer Res; 2006 Oct; 66(20):9937-47. PubMed ID: 17047056
[TBL] [Abstract][Full Text] [Related]
6. GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance.
Luo W; Gangwal K; Sankar S; Boucher KM; Thomas D; Lessnick SL
Oncogene; 2009 Nov; 28(46):4126-32. PubMed ID: 19718047
[TBL] [Abstract][Full Text] [Related]
7. A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature.
Hancock JD; Lessnick SL
Cell Cycle; 2008 Jan; 7(2):250-6. PubMed ID: 18256529
[TBL] [Abstract][Full Text] [Related]
8. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma.
Kinsey M; Smith R; Iyer AK; McCabe ER; Lessnick SL
Cancer Res; 2009 Dec; 69(23):9047-55. PubMed ID: 19920188
[TBL] [Abstract][Full Text] [Related]
9. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma.
Owen LA; Kowalewski AA; Lessnick SL
PLoS One; 2008 Apr; 3(4):e1965. PubMed ID: 18414662
[TBL] [Abstract][Full Text] [Related]
10. Microsatellites are EWS/FLI response elements: genomic "junk" is EWS/FLI's treasure.
Gangwal K; Lessnick SL
Cell Cycle; 2008 Oct; 7(20):3127-32. PubMed ID: 18927503
[TBL] [Abstract][Full Text] [Related]
11. Emergent Properties of EWS/FLI Regulation via GGAA Microsatellites in Ewing's Sarcoma.
Gangwal K; Close D; Enriquez CA; Hill CP; Lessnick SL
Genes Cancer; 2010 Feb; 1(2):177-187. PubMed ID: 20827386
[TBL] [Abstract][Full Text] [Related]
12. The inositol phosphatase SHIP-1 is negatively regulated by Fli-1 and its loss accelerates leukemogenesis.
Lakhanpal GK; Vecchiarelli-Federico LM; Li YJ; Cui JW; Bailey ML; Spaner DE; Dumont DJ; Barber DL; Ben-David Y
Blood; 2010 Jul; 116(3):428-36. PubMed ID: 20445019
[TBL] [Abstract][Full Text] [Related]
13. A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells.
Girnita L; Girnita A; Wang M; Meis-Kindblom JM; Kindblom LG; Larsson O
Oncogene; 2000 Aug; 19(37):4298-301. PubMed ID: 10980604
[TBL] [Abstract][Full Text] [Related]
14. Identification of diterpenoid compounds that interfere with Fli-1 DNA binding to suppress leukemogenesis.
Liu T; Xia L; Yao Y; Yan C; Fan Y; Gajendran B; Yang J; Li YJ; Chen J; Filmus J; Spaner DE; Zacksenhaus E; Hao X; Ben-David Y
Cell Death Dis; 2019 Feb; 10(2):117. PubMed ID: 30741932
[TBL] [Abstract][Full Text] [Related]
15. Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro.
Chansky HA; Barahmand-Pour F; Mei Q; Kahn-Farooqi W; Zielinska-Kwiatkowska A; Blackburn M; Chansky K; Conrad EU; Bruckner JD; Greenlee TK; Yang L
J Orthop Res; 2004 Jul; 22(4):910-7. PubMed ID: 15183454
[TBL] [Abstract][Full Text] [Related]
16. Novel flavagline-like compounds with potent Fli-1 inhibitory activity suppress diverse types of leukemia.
Song J; Yuan C; Yang J; Liu T; Yao Y; Xiao X; Gajendran B; Xu D; Li YJ; Wang C; Liu W; Wen M; Spaner D; Filmus J; Zacksenhaus E; Zhang Y; Hao X; Ben-David Y
FEBS J; 2018 Dec; 285(24):4631-4645. PubMed ID: 30387554
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of apoptosis by normal and aberrant Fli-1 and erg proteins involved in human solid tumors and leukemias.
Yi H; Fujimura Y; Ouchida M; Prasad DD; Rao VN; Reddy ES
Oncogene; 1997 Mar; 14(11):1259-68. PubMed ID: 9178886
[TBL] [Abstract][Full Text] [Related]
18. Regulatory role of mevalonate and N-linked glycosylation in proliferation and expression of the EWS/FLI-1 fusion protein in Ewing's sarcoma cells.
Wang M; Xie Y; Girnita L; Nilsson G; Dricu A; Wejde J; Larsson O
Exp Cell Res; 1999 Jan; 246(1):38-46. PubMed ID: 9882513
[TBL] [Abstract][Full Text] [Related]
19. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma.
Smith R; Owen LA; Trem DJ; Wong JS; Whangbo JS; Golub TR; Lessnick SL
Cancer Cell; 2006 May; 9(5):405-16. PubMed ID: 16697960
[TBL] [Abstract][Full Text] [Related]
20. The Fli-1 proto-oncogene, involved in erythroleukemia and Ewing's sarcoma, encodes a transcriptional activator with DNA-binding specificities distinct from other Ets family members.
Zhang L; Lemarchandel V; Romeo PH; Ben-David Y; Greer P; Bernstein A
Oncogene; 1993 Jun; 8(6):1621-30. PubMed ID: 8502483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
